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INTRODUCTION
The last decade has been witness to an exponential
increase in our understanding of the fundamental
mechanisms involved in hepatic bile formation and
intrahepatic cholestasis, defined herein as impaired for-
mation of canalicular bile. This review will provide a
summary of recent experimental work, with particular
reference to the clinical implications of this informa-
tion. For further in-depth discussions of this subject,
interested readers are referred to several recent reviews
(1-6).
Bile formation, believed to be an osmotic process
resulting from the active secretion of solutes followed
by passive water movement, has long been conceptually
divided into bile acid-dependent and bile acid inde-
pendent (BAIBF) components (Fig. 1). Bile acid-de-
pendent bile fiow is conventionally defined as the slope
of the line relating canalicular bile fiow to bile acid
output (1,3), and BAIBF as the extrapolated y-intercept
of this line. While useful for discussion purposes, the
limitations of this approach to studies of bile formation
are readily apparent (1,3) and it is best to consider the
mechanisms responsible for the formation of these two
components interrelated.
HEPATIC UPTAKE MECHANISMS
Recent studies have indicated that transhepatocytic
movement of taurocholate, as a representative bile acid,
from sinusoid to canaliculus is driven by the transmem-
brane gradient for sodium across the sinusoidal mem-
brane and by the negative intracellular potential differ-
ence across the canalicular membrane (7, 8). The activ-
ity of sinusoidal Na"',K"* -̂ATPase (9) is believed to be
critical in the maintenance of these two driving forces
(see Fig. 2). Several studies have addressed the binding
properties of bile acids to specific membrane sites (10,
11) and a putative bile acid membrane transport protein
has been recently characterized (12-14). Of clinical
import, photolabile derivatives of phalloidin, the bi-
cyclic toxic heptapeptide from the poisonous mush-
room Amanita phalloides (15), and antamanide, a de-
rivative from the same toadstool, also bind to this same
protein (16). These findings provide an explanation not
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only for the hepatotropism exhibited by phallotoxins,
but also for the protective effect of antamanide (17)
and other organic anions, such as penicillin, that may
compete for the same carrier protein.
INTRACELLULAR TRANSPORT
In contrast to hepatic uptake mechanisms, the steps
involved in intracellular transport of bile acids and
other organic anions are not well established. Cytosolic
glutathione-S-transferases (18) and other recently iden-
tified proteins (19) appear to be the major intracellular
binders of bile acids and other organic anions. Vesicular
transport of bile acids, similar to that described for IgA
(20), has been suggested by ultrastructural studies of
hepatocytes during bile acid-induced choleresis (21).
Further support for this hypothesis has resulted from
recent studies examining the mechanisms of bile acid
transport in subcellular fractions of rat liver (22). Iden-
tification ofthe steps involved continues to be an active
area of research, since intracellular transport and can-
alicular secretion, rather than sinusoidal uptake, appear
to be rate-determining steps for bile acid transport (23,
24). Based on ultrastructural observations, the Golgi
apparatus has been postulated to be the site of the
defect in bile secretion that accounts for the cholestasis
observed in arteriohepatic dyplasia (25).
ELECTROLYTE TRANSPORT MECHANISMS
The importance of electrolyte transport processes on
the plasma membrane in the elaboration of bile has
also been the focus of recent work (see Refs. 3 and 6).
Earlier work consistent with a role of bicarbonate in
bile formation (26-28) led, in part, to the identification
and characterization of a canalicular chloride:bicar-
bonate (29) and a sinusoidal sodium:proton exchanger
(30, 31), that may be functionally "coupled" to generate
an osmotic driving force for BAIBF (6, 29, 30). Indirect
observations supporting this view include: 1) the cho-
lestasis, observed with the estrogen, ethinyl estradiol, is
associated with diminished sodium:proton exchange
activity (32); 2) glucocorticoids and thyroid hormone,
both shown to stimulate BAIBF (33, 34), also result in
enhanced sodium:proton exchange (35, 36); 3) urso-
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FIG. 1. Schematic representation of bile acid-dependent










FIG. 2. Proposed model of bile formation that incorporates mem-
brane transport processes and inhibitors (shaded arrows) and stimu-
lants (open arrows) of these processes. CAH, carbonic anhydrase;
UDCA, ursodeoxycholate;El, primary active transport process (e.g.,
Na*,K*-ATPase);JIl, exchange mechanism (or antiport); III, second-
ary active transport process (e.g., Na'̂ -coupled bile acid transport).
deoxycholate, a dihydroxy bile acid, associated with
enhanced canalieular bicarbonate secretion (37), ap-
pears to act via the sodium:proton antiport (38, 39);
and 4) acetazolamide, an inhibitor of carbonic anhy-
drase, necessary, in part, for the intracellular generation
of bicarbonate, causes a reduction in bile flow under
ursodeoxycholate-stimulated conditions (40).
These findings provide an alternative model (see Fig.
2) to previous concepts of bile formation that attempted
to directly correlate bile flow to Na"̂ ,K"̂ -ATPase activ-
ity. Thus, whereas a number of experimental agents
have been shown to increase (thyroid hormone, tauro-
cholate) or decrease (ethinyl estradiol, chlorpromazine)
Na" ,̂K'*'-ATPase activity, a consistent relationship be-
tween enzyme activity and bile flow has not always
been observed (41).
CANALICULAR CONTRACTION
The role that canalieular contraction plays in bile
formation remains uneiear. Nevertheless, coordinated
contractions of canalieular microfilaments have been
observed in isolated rat hepatocytes (42, 43) and pri-
mary monolayer cultures (44), that are sensitive to
intracellular calcium (45,46) as well as bile salt concen-
tration (47). Norethandrolone-induced eholestasis may
be related to altered microfilament function (48). The
phenothiazine, ehlorpromazine, induces cholestatic
jaundice in 1-2% of treated patients (49) and asymto-
matic liver function abnormalities in up to 50% of
patients (50). Chlorpromazine and its nietabolites aflect
the polymerization of actin to its filamentous form (51),
and ultrastructural changes observed during chlor-
promazine-induced cholestasis resemble those induced
by microfilament inhibitors (52). Work with microtu-
bule inhibitors, such as eolchicine, suggests that this
component of the cytoskeleton may also play a role in
bile formation (53, 54). Drug-induced eholestasis, such
as observed with chlorpromazine, had been considered
largely nonfatal until reports of hepatic injury with
benoxaprofen, a nonsteroidal antiinflammatory drug,
began to circulate (55, 56). The mechanism of this
unusual cholestatic reaction remains to be elucidated,
hampered by the scanty information contained in case
reports, but alteration of biliary contractility and/or
direct injury to the canalieular membrane has been
proposed to explain the unique ductular concretions
manifested histologically.
DUCTULAR MODIFICATIONS
Somatostatin has been shown to exert an antichol-
eretic effect in dogs, unrelated to hemodynamic eflects
(57, 58), that is thought to be mediated by a local eflect
on the bile ductular cells (57). If clinically significant,
somatostatin-induced concentration of bile, the result
of either increased ductular reabsorption or suppressed
ductular secretion, might lead to decreased susceptibil-
ity to cholesterol precipitation and subsequent gallstone
formation (57).
MEMBRANE FLUIDITY
The micro viscosity of the hepatocyte membrane may
also be a factor in bile formation. Ethinyl estradiol
decreases hepatocyte plasma membrane fluidity (by
increasing the cholesterol/phospholipid ratio in the
membrane) with a concomitant reduction in Na"̂ ,K'̂ -
ATPase activity (59). Nonionic detergents, such as Tri-
ton WR-1339, have been shown to reverse the de-
creased membrane fluidity assoeiated with estrogen
administration and return bile flow and bile excretion
to normal values (60). Chlorpromazine-induced choles-
tasis also may result, in part, from an alteration in
membrane fluidity (61). On the other hand, cortisol
and thyroid hormone, agents associated with choleresis,
increase membrane fluidity and Na'̂ ,K"^-ATPase activ-
ity (62). However, the exact relationship between mem-
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brane fluidity and bile secretion remains unclear. Thus,
cholestasis can be induced with ethinyl estradiol with-
out an observable change in membrane fluidity (63),
and canrenoate, a congener of the active metabolite of
spironolactone, decreases membrane fluidity without a
concomitant decrease in bile formation (64). Spirono-
lactone, itself, has been shown to increase BAIBF (65).
SELECTED CLINICAL CORRELATES
The pathogenesis of total parenteral nutrition (TPN)-
associated cholestasis is unknown. The cholestatic bile
acid, lithocholate, formed by bacterial 7-a-dehydrox-
ylation of chenodeoxycholate in the intestinal tract (66),
has recently been implicated (67). The contribution of
lithocholate to the total bile acid pool of duodenal bile
obtained by duodenal drainage increased in five of 15
patients with inflammatory bowel disease on TPN and
correlated with liver function abnormalities (67). In
support of these flndings, antibiotic administration to
patients with inflammatory bowel disease on TPN, to
reduce intestinal bacterial production of lithocholate,
prevented hepatic abnormalities in comparison to con-
trol patients (68). Abnormal bile acid metabolism lead-
ing to increased levels of lithocholate may also play an
etiological role in Byler's disease, an autosomal reces-
sive form of fatal intrahepatic cholestasis (69, 70).
A reduction in bile acid-independent bile flow, pos-
sibly via a reduction in Na'̂ ,K'̂ -ATPase activity, is
considered to be a possible explanation for lithocholate-
induced intrahepatic cholestasis (71). Alternatively,
changes in canalicular membrane structure, specifically
an increase in the cholesterol to phospholipid ratio,
leading to altered permeability, may be involved (72).
Recently, the ability of cholestatic bile acids to bind
calcium was postulated to be related, in part, to the
pathogenesis of lithocholate-induced cholestasis (73).
This interaction of lithocholate and its derivatives with
calcium, by inducing histamine release by tissue mast
cells, has also been implicated in the disabling pruritus
that affects some patients with cholestasis (74).
Amino acids have also been associated with hepatic
dysfunction and cholestasis during TPN administration
(75), and with reductions in bile acid independent bile
flow (76). The intriguing possibility that this may be
the result of amino acid inhibition of sodium-depend-
ent bile acid transport, via a dissipation of the trans-
membrane sodium gradient, has been the focus of
recent studies (77, 78).
In addition, the observation that Escherichia coli
endotoxin causes a dimunition in bile flow (79), asso-
ciated with a decrease in Na'̂ ,K"^-ATPase activity (80),
may offer an explanation for the intrahepatic cholestasis
seen during severe bacterial infections (81). A case
report of jaundice associated with an extrahepatic gram-
positive infection was attributed to an endotoxin-like
activity of circulating free teichoic acid (82).
Despite advances in our understanding of the mech-
anisms of bile formation and cholestasis, application of
this information to the therapy of cholestatic liver in-
jury remains Hmited. The cholestasis and lithogenic bile
secretion associated with estrogen use may be regarded
as a notable exception. While the actual incidence of
estrogen-induced cholestasis is not known, groups at
increased risk include Scandinavians (83), Chileans
(84), and women with the Dubin-Johnson syndrome
(85) or with a history of intrahepatic cholestasis of
pregnancy (86), a syndrome believed to be the result of
an abnormal reaction of the maternal liver to endoge-
nous estrogen (87, 88). Experimental work has attrib-
uted estrogen-induced cholestasis primarily to altera-
tions in liver plasma membrane lipid structure or
Na"',K"'-ATPase activity (59, 60) although this does not
fully account for the wide differences in individual
susceptibility to the cholestatic effect. Administration
ofthe methyl donor, S-adenosyl-L-methionine (SAMe),
leads to reversal of estrogen-induced impairment of bile
flow in rats (89). This protective effect of SAMe may
be due, in part, to alterations in membrane lipid fluidity
and Na"̂ ,K"̂ -ATPase activity (63). Alternatively en-
hanced formation of methyl-derivatives of estrogen
(89), preventing binding of estrogen to hepatic micro-
somal proteins (90), may be involved. In a randomized,
single-blind clinical study, SAMe administration (800
mg iv/day) was shown to be effective in the treatment
of intrahepatic cholestasis of pregnancy (91). The rele-
vance of these findings to other forms of intrahepatic
cholestasis is the basis of current investigations. Perti-
nent in this regard are preliminary observations that
demonstrate that SAMe confers a hepatocytoprotective
effect and increases bile acid secretory rate maximum
in taurolithocholate-induced cholestasis (92).
Clearly, much more remains to be understood re-
garding the mechanisms involved in bile formation.
Eflective management of disease processes has always
been contingent on a thorough understanding of nor-
mal as well as pathophysiological mechanisms. Never-
theless, several new findings and areas of research have
been discussed herein that promise to bring us closer to
an understanding with potential therapeutic implica-
tions.
Reprint requests: Dr. Richard H. Moseley, VA Medical Center,
Department of Internal Medicine, 2215 Fuller Road, Ann Arbor, MI
48105.
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45. Watanabe S, Philips MJ. Câ * causes active contraction of bile
canaliculi: direct evidence from microinjection studies. Proc Natl
Acad Sci USA 1984;81:6164-8.
46. Watanabe S, Smith CR, Philips MJ. Coordination of the con-
tractile activity of bile canaliculi: evidence from calcium microin-
jection of triplet hepatocytes. Lab Invest 1985;53:275-9.
47. Miyairi M, Oshio C, Watanabe S, et al. Taurocholate accelerates
bile canalicular contractions in isolated rat hepatocytes. Gastro-
enterology 1984;87:788-92.
48. Philips MJ, Oda M, Funatsu K. Evidence for microfilament
involvement in norethandrolone-induced cholestasis. Am J Pa-
thol 1978;93:729-44.
49. Ishak KG, Nelson SI. Hepatic injury associated with the pheno-
thiazines. Arch Pathol 1972;93:283-304.
50. Bartholomew LG, Cain JC, Frazier SH, et al. Effects of chlor-
promazine on the liver. Gastroenterology 1958;34:1096-107.
51. Elias E, Boyer JL. Chlorpromazine and its metabolites alter
polymerization and gelation of actin. Science 1979;206:1404-6.
September 1986 MECHANISMS OF BILE FORMATION AND CHOLESTASIS 735
52. Hraban Z, Tavoloni N, Reed JS, et al. Ultrastructural changes
during cholestasis induced by chlorpromazine in the isolated
perfused rat liver. Virchows Arch B Cell Pathol 1978;26:289-
305.
53. FukumotoY, Okita K, Ando K, etal. Influence of colchicine on
bile secretion. Hepatology 1982,2:160 (abstr).
54. Dubin M, Maurice M, Feldman G, et al. Influence of colchicine
and phalloidin on bile secretion and hepatic ultrastructure in the
rat: possible interaction between microtubules and microfila-
ments. Gastroenterology 1980;79:646-54.
55. Taggart HM, Alderdice JM. Fatal cholestatic jaundice in elderly
patients taking benoxaprofen. Br Med J 1982;284:1372.
56. Duthie A, GlanfieldP, Nicholls A, etal. Fatal cholestatic jaundice
in elderly patients taking benoxaprofen. Br Med J 1982,285:62.
57. Rene E, Danzinger RG, Hofmann AF, et al. Pharmacologic
effect of somatostatin on bile formation in the dog: enhanced
ductular reabsorption as the major mechanism of anticholeresis.
Gastroenterology 1983;84:120-9.
58. Hanks FB, Kortz WJ, Andersen DK, et al. Somatostatin sup-
pression of canine fasting bile secretion. Gastroenterology
1983;84:130-7.
59. Davis RA, Kem F, Showalter R, et al. Alterations of hepatic
Na" ,̂K*-ATPase and bile flow by estrogen: effects on liver surface
membrane lipid structure and function. Proc Natl Acad Sci USA
1978;75:4130-4.
60. Simon FR, Gonzalez M, Sutherland E, et al. Reversal of ethinyl
estradiol-induced bile secretory failure with Triton WR-1339. J
Clin Invest 1980;65:851-60.
61. Keefe EB, Blankenship NM, Scharschmidt BF. Alteration of rat
liver plasma membrane fluidity and ATPase activity by chlor-
promazine hydrochloride and its metabolites. Gastroenterology
1980;79:222-31.
62. Keefe EB, Scharschmidt BF, Blankenship NM, et al. Studies of
relationships among bile flow, liver plasma membrane NaK-
ATPase, and membrane microviscosity in the rat. J Clin Invest
1979;64:1590-8.
63. Boelsterii UA, Rakhit G, Balazs T. Modulation by S-adenosyl-
L-methionine of hepatic (Na* + K*)-ATPase, membrane fluidity,
and bile flow in rats with ethinyl estradiol-induced cholestasis.
Hepatology 1983;3:12-17.
64. Miner PB, Sneller M, Crawford SS. Spironolactone- and canren-
one-induced changes in hepatic (Na*,K*)ATPase activity, surface
membrane cholesterol and phospholipid, and fluorescence polar-
ization in the rat. Hepatology 1983;3:481-8.
65. Zsigmond G, Solymoss B. Increased canalicular bile production
induced by pregnenolone-16a-carbonitrile, spironolactone and
cortisol in rats. Proc Exp Biol Med 1974;145:631-5.
66. Danielsson H. Mechanisms of bile acid biosynthesis. In: Nair PP,
Kritchevsky D, eds. The bile acids, Vol 2. Physiology and metab-
olism. New York: Plenum Press, 1973:1-32.
67. Fouin-Fortunet H, Le Quemec L, Erlinger S, et al. Hepatic
alterations during total parenteral nutrition in patients with in-
flammatory bowel disease: a possible consequence of lithocholate
toxicity. Gastroenterology 1982,82:932-7.
68. Capron JP, Gineston JL, Herve MA, et al. Metronidazole in
prevention of cholestasis associated with total parenteral nutri-
tion. Lancet 1983; 1:446-7.
69. Williams CN, Kaye R, Baker L, et al. Progressive familial cho-
lestatic cirrhosis and bile acid metabolism. J Pediatr
1972;81:493-500.
70. Linarelli LG, Williams CN, Phillips MJ. Byler's disease: fatal
intrahepatic cholestasis. J Pediatr 1972,81:484-92.
71. Kakis G, Yousef IM. Pathogenesis of lithocholate-and taurolith-
ocholate-induced intrahepatic cholestasis in rats. Gastroenterol-
ogy 1978;75:595-607.
72. Kakis G, Phillips MJ, Yousef IM. The respective roles of mem-
brane cholesterol and of sodium potassium adenosine triphos-
phatase in the pathogenesis of lithocholate-induced cholestasis.
U b Invest 1980;43:73-81.
73. Oelberg DG, Dubinsky WP, Adcock EW, et al. Calcum binding
by lithocholic acid derivatives. Am J Physiol 1984;247:G112-15.
74. Little JM, Cage K, Oelberg DG, et al. Pathogenesis ofthe pruritus
of cholestasis: an initial hypothesis. Hepatology 1985;5:1005
(abstr).
75. Dahms BB, Halpin TC. Serial liver biopsies in parenteral nutri-
tion-associated cholestasis of early infancy. Gastroenterology
1981;81:136-44.
76. Perea A, Tuchweber B, Roy CC, et al. Decreased bile acid
independent flow as a possible cause of amino acid-induced
cholestasis. Gastroenterology 1982;82:1258 (abstr).
77. Blitzer BL, Ratoosh SL, Donovan CB. Amino acid inhibition of
bile acid uptake by isolated rat hepatocytes: relationship to dis-
sipation of transmembrane Na* gradient. Am J Physiol
1983;245:G399-403.
78. Blitzer BL, Bueler RL. Amino acid inhibition of bile acid uptake
by basolateral liver plasma membrane (LPM) vesicles. Gastro-
enterology 1983;84:1364 (abstr).
79. Utili R, Abemathy CO, Zimmerman HJ. Cholestatic effects of
Escherichia coli endotoxin on the isolated perfused rat liver.
Gastroenterology 1976;70:248-53.
80. Utili R, Abemathy CO, Zimmerman HJ. Inhibition of Na*,K*-
adenosine triphosphatase by endotoxin: a possible mechanism
for endotoxin-induced cholestasis. J Infect Dis 1977; 136:583-7.
81. Miller DJ, Keeton GR, Webber BL, et al. Jaundice in severe
bacterial infection. Gastroenterology 1986;71:94-7.
82. Rose HD, Lentino JR, Mavrelis PG, et al. Jaundice associated
with nonhepatic Staphylococcus aureus infection: does teichoic
acid have a role in pathogenesis? Dig Dis Sci 1982;27:1046-50.
83. Urrson-Cohn U, Stenram U. Liver ultrastructure and function
in icteric and non-icteric women using oral contraceptives. Acta
Med Scand 1967;181:257-64.
84. Orellana-Alcalde JM, Dominguez JP. Jaundice and oral contra-
ceptive drugs. Uncet 1966;2:1278-80.
85. Cohen L, Lewis C, Arias IM. Pregnancy, oral contraceptives, and
chronic fkmilial jaundice with predominantly conjugated hyper-
bilirubinemia (Dubin-Johnson syndrome). Gastroenterology
1972;62:1182-90.
86. Reyes H, Ribalta J, Gonzalez MC, et al. Sulfobromophthalein
clearance tests before and after ethinyl estradiol administration,
in women and men with family history of intrahepatic cholestasis
of pregnancy. Gastroenterology 1981 ;81:226-31.
87. Holzbach RT. Jaundice in pregnancy. Am J Med 1976;61:367-
76.
88. Reyes H. The enigma of intrahepatic cholestasis of pregnancy:
lessons from Chile. Hepatology 1982;2:87-96.
89. Stramentinoli G, Di Padova C, Gualano M, et al. Ethynylestra-
diol-induced impairment of bile secretion in the rat: protective
effect of S-adenosyl-L-methionine and its implication in estrogen
metabolism. Gastroenterology 1981;80:154-8.
90. Stramentinoli G, Gualano M, Rovagnati P, et al. Influence of S-
adenosyl-L-methionine on irreversible binding of ethynylestradiol
to rat liver microsomes, and its implication in bile secretion.
Biochem Pharmacol 1979,28:981-4.
91. Freeza M, Pozzato G, Chiesa L, et al. Reversal of intrahepatic
cholestasis of pregnancy in women after high dose S-adenosyl-L-
methionine administration. Hepatology 1984;4:274-8.
92. Schreiber AJ, Warren G, Sutherland E, et al. Enhancement of
taurocholate secretory maximum: S-adenosyl methionine
(SAM)-induced cytoprotection. Clin Res 1983;31:86A (abstr).

